Doxorubicin: nanotechnological overviews from bench to bedside. Issue 2 (February 2017)

• Record Type: Journal Article
• Authors: Cagel, Maximiliano; Grotz, Estefanía; Bernabeu, Ezequiel; Moretton, Marcela A.; Chiappetta, Diego A.
• Is Part Of: Drug discovery today. Volume 22:Issue 2(2017)
• Page Start: 270
• Page End: 281
• Publication Date: 2017-02
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2016.11.005
• Languages: English
• ISSNs: 1359-6446

Abstract

Graphical abstract: Highlights: Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents. Dose-cumulative cardiotoxicity is the most dangerous adverse effect. DOX-based nanoformulations have been designed to diminish serious adverse effects. DOX-loaded nanoproducts approved by the regulatory agencies have been described. Only one nanotechnological targeted DOX product is evaluated in clinical trials. Abstract : Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer–drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics. Abstract : This review provides an overview of the current state of the passively and actively targeted nanotechnological-based DOX formulations, some approved by regulatory agencies and others still in clinical trials.